Pharmaceutical Contract Manufacturing Market To Reach $310.97 Billion By 2033

Pharmaceutical Contract Manufacturing Market Growth & Trends

The global pharmaceutical contract manufacturing market size is expected to reach USD 310.97 billion by 2033, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 10.45% from 2026 to 2033. Growth in the market can be attributed to benefits offered to pharmaceutical companies, such as cost efficiencies, the ability to leverage contract manufacturing facilities to streamline production, and the opportunity to focus on core competencies. In addition, the market is driven by the increasing demand for biologics, biosimilars, high-potency active pharmaceutical ingredients (HPAPIs), and personalized medicine.

The expansion of pharmaceutical companies into new product innovations has led to the increased demand for contract manufacturing organization (CMO) services for clinical trials, packaging, and regulatory compliance. Technological integrations among CMOs, such as continuous manufacturing, automation, and AI-driven process optimization, are further propelling pharmaceutical production. These innovations enhance efficiency, reduce waste, and improve product quality and standards.

The pharmaceutical contract manufacturing industry is expected to experience continued growth during the forecast period, as CMO providers play a crucial role in helping companies meet the regulatory requirements of the FDA, EMA, and ICH. Moreover, the growing demand for both branded and generic drugs is a significant factor in the expansion of the pharmaceutical contract manufacturing industry. As various generic drugs reach patent expiration, pharmaceutical companies are innovating new generic versions to meet this demand. Hence, many of these pharmaceutical companies are relying on CMO services to fulfill market needs efficiently and effectively.

In addition, regulation is one of the significant factors for pharmaceutical products that have fueled the demand for pharmaceutical contract manufacturing. The FDA plays a pivotal role in ensuring the safety and efficiency of pharmaceuticals in the market. Likewise, strategic partnerships and accelerating product launches drive market growth. For instance, in December 2024, Lonza mentioned the expansion of its service offering orally delivered biologic therapies to support innovative capsule companies' unique development and manufacturing needs. The product launch will help patients explore innovative delivery solutions to mitigate bioavailability challenges.

 Request a free sample copy or view report summary: Pharmaceutical Contract Manufacturing Market Report

Pharmaceutical Contract Manufacturing Market Report Highlights

• Based on service segment, the market is segmented into API Manufacturing, finished drug product manufacturing, and packaging services.

• Based on product segment, the market is segmented into small molecules and biologics. Biologics further includes monoclonal antibodies, vaccines, recombinant proteins, and others.

• On the basis of drug segment, the market is segmented into generics and branded.  The generics segment accounted for the largest market share in 2025.

• On the basis of the scale of the operation segment, the market is segmented into batch and continuous segments.

• On the basis of the workflow segment, the market is segmented into clinical and commercial. The commercial segment dominated the global market in 2025 owing to a strong pipeline for pharmaceutical drug development, and large-scale commercial manufacturing, among others.

• On the basis of the application segment, the market is segmented into oncology, infectious diseases, neurological disorders, cardiovascular diseases, metabolic disorders, autoimmune diseases, respiratory diseases, ophthalmology, gastrointestinal disorders, hormonal disorders, hematological disorders, and others.

• On the basis of the end use segment, the market is segmented into pharmaceutical and biotechnology companies.

• On the basis of the company size segment, the market is segmented into small, medium, and large. The small company size segment dominated the market with the largest revenue share in 2025.

• The North American pharmaceutical contract manufacturing industry accounted for the largest share of 38.44% in 2025.

Pharmaceutical Contract Manufacturing Market Segmentation

Grand View Research has segmented the global pharmaceutical contract manufacturing market on the basis of service, product, scale of operation, workflow, application, end use, company size, and region:

Pharmaceutical Contract Manufacturing Service Outlook (Revenue, USD Million, 2021 - 2033)

• API Manufacturing

• Finished Drug Product Manufacturing

  • Oral Solids

  • Liquids

  • Topical

  • Others

• Packaging Services

Pharmaceutical Contract Manufacturing Product Outlook (Revenue, USD Million, 2021 - 2033)

• Small Molecule

• Biologics

  • Monoclonal Antibodies

  • Vaccines

  • Recombinant Proteins

  • Others

Pharmaceutical Contract Manufacturing Drug Outlook (Revenue, USD Million, 2021 - 2033)

• Generics

• Branded

Pharmaceutical Contract Manufacturing Scale of Operation Outlook (Revenue, USD Million, 2021 - 2033)

• Batch

• Continuous

Pharmaceutical Contract Manufacturing Workflow Outlook (Revenue, USD Million, 2021 - 2033)

• Clinical 

• Commercial

Pharmaceutical Contract Manufacturing Application Outlook (Revenue, USD Million, 2021 - 2033)

• Oncology

• Infectious Diseases

• Neurological Disorders

• Cardiovascular Disease

• Metabolic Disorders

• Autoimmune Diseases

• Respiratory Diseases

• Ophthalmology

• Gastrointestinal Disorders

• Hormonal Disorders

• Hematological Disorders

• Others

Pharmaceutical Contract Manufacturing End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Pharmaceutical Companies

• Biotechnology companies

Pharmaceutical Contract Manufacturing Company Size Outlook (Revenue, USD Million, 2021 - 2033)

• Small

• Medium

• Large

Pharmaceutical Contract Manufacturing Regional Outlook (Revenue, USD Million, 2021 - 2033) 

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy 

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand 

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Oman

  • Qatar

List of Key Players of Pharmaceutical Contract Manufacturing Market

• AbbVie Contract Manufacturing

• Almac Group

• Boehringer Ingelheim BioXcellence

• Catalent

• Dr. Reddy's Laboratories

• Fareva

• Fujifilm Diosynth Biotechnologies

• Jubilant HollisterStier

• Lonza Group

• Patheon (Thermo Fisher Scientific)

• Pfizer CentreOne

• Prakruti Life Science

• Recipharm

• Samsung Biologics

• Siegfried Holding AG

• Vetter Pharma

• WuXi AppTec